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ABSTRACT
Aims To assess the cost-effectiveness of a two-component intervention designed to increase attendance at the NHS
Stop Smoking Services (SSSs) in England. Design Cost-effectiveness analysis alongside a randomized controlled trial
(Start2quit). Setting NHS SSS and general practices in England. Participants The study comprised 4384 smokers aged
16 years or more identiﬁed from medical records in 99 participating practices, who were motivated to quit and had not
attended the SSS in the previous 12months. Intervention and comparator Intervention was a personalized and tailored
letter sent from the general practitioner (GP) and a personal invitation and appointment to attend a taster session providing
information about SSS. Control was a standard generic letter from theGPadvertising SSS and asking smokers to contact the
service to make an appointment. Measurements Costs measured from an NHS/personal social services perspective,
estimated health gains in quality-adjusted life-years (QALYs) measured with EQ-5D and incremental cost per QALY gained
during both 6months and a life-time horizon. Findings During the trial period, the adjusted mean difference in costs was
£92 [95% conﬁdence interval (CI) = –£32 to –£216) and the adjusted mean difference in QALY gains was 0.002 (95%
CI = –0.001 to 0.004). This generates an incremental cost per QALY gained of £59401. The probability that the tailored
letter and taster session is more cost-effective than the generic letter at 6 months is never above 50%. In contrast, the
discounted life-time health-care cost was lower in the intervention group, while the life-time QALY gains were signiﬁcantly
higher. The probability that the intervention is more cost-effective is more than 83% using a £20000–30000 per QALY-
gained decision-making threshold. Conclusions An intervention designed to increase attendance at the NHS Stop
Smoking Services (tailored letter and taster session in the services) appears less likely to be cost-effective than a generic letter
in the short term, but is likely to become more cost-effective than the generic letter during the long term.
Keywords Cost-effectiveness, personal tailored risk information, randomized controlled trial, smoking cessation, stop
smoking services, uptake of service.
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INTRODUCTION
Smoking is the greatest avoidable cause of mortality and
morbidity, and a major public health problem in the
United Kingdom [1,2]. Half of smokers will die prematurely
due to smoking-related disease, such as lung cancer,
chronic obstructive pulmonary disease (COPD) or coronary
heart disease (CHD), and lose an average of 8 years of life
[3]. The prevalence of smoking in the United Kingdom
has dropped from 45% in the 1960s to 19% in 2013;
however, the reduction has slowed during the past 5 years
[4]. The NHS spends more than £5 billion a year on
treating smoking-related diseases, and the societal cost of
smoking is approximately £14 billion a year when loss of
productivity and economic output due to smoking-related
illness and premature death are taken into account [5,6].
Government-funded specialist smoking cessation ser-
vices, now known as the NHS Stop Smoking Services
(SSSs), were established by Primary Care Trusts (PCTs)
throughout England in 2000 [7]. The SSSs provide free,
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tailored support to all smokers willing to quit, providing a
combination of recommended stop smoking pharmaco-
therapies [nicotine replacement therapy (NRT), bupropion
and varenicline] and behavioural support (e.g. group or
one-to-one support). Among smokers who set a quit date
through the SSSs, 48% had quit successfully (self-reported
2 weeks abstinence at 4 weeks after the designated quit
rate), and 70% of these quitters had their results conﬁrmed
by expired carbon monoxide (CO) veriﬁcation [8,9].
However, despite the relatively high quit rate, at least in
the short term, smokers are not taking full advantage of
the services. The proportion of smokers in England using
the SSSs in 2011was only 4.1% [10]. In view of the recent
cuts to smoking cessation budgets and the decline of
services in England, new approaches are needed and op-
portunities to tackle smoking within the NHS maximized
[11]. A large randomized controlled trial (RCT) (Start2quit
trial: ISRCTN 76561916) was conducted to test the effec-
tiveness and cost-effectiveness of a two-component inter-
vention designed to increase attendance at the SSS in
England. In a companion paper, we report the ﬁndings on
clinical effectiveness [12]. This report presents a cost-
effectiveness analysis carried out alongside the Start2quit
trial to assess the value for money of the intervention.
METHODS
Randomized controlled trial
The Start2quit trial was a pragmatic two-arm RCT of a
two-component intervention. The study recruited 4384
smokers aged 16 years or more identiﬁed from medical
records in 99 participating practices, who were motivated
to quit and had not attended the SSS in the previous 12
months. A total of 1748 participants were randomized to
the control group and received a standard generic letter
from the general practitioner (GP) advertising the local
SSS and asking the smoker to contact the service to make
an appointment to see an adviser. Smokers allocated to
the intervention group (n= 2636) received a brief personal-
ized tailored letter sent from the GP using information
obtained from abaseline questionnaire and frommedical re-
cords; they also received a personal invitation and appoint-
ment to attend a ‘Come and Try it’ taster session to ﬁnd out
more about the services, with the session run by advisers
from the local SSS. One participant in the intervention
group withdrew from the study, leaving 4383 participants
analysed. Full details of the design of the Start2quit trial
have been reported in the published study protocol [13].
Resource use and costs
Costs were estimated from an NHS/Personal Social Ser-
vices (PSS) perspective to reﬂect the English NHS
decision-making framework [14]. We assessed all costs in
UK pounds sterling (£) at 2012–13 prices or adjusted them
accordingly using the Hospital and Community Health Ser-
vices (HCHS) pay and price inﬂation index [15].
Data on the use of resources were collected at the level
of individual participants.We recorded resource use associ-
ated with the delivery of the trial interventions, including
staff time spent in delivering treatment, consumables (such
as postage and printing) and resources required for train-
ing the advisers in the delivery of the taster sessions. We
also collected participants’ use during the previous 6
months of health and social care services using a
comprehensive service use questionnaire at both baseline
and 6-month follow-up. The volume of resource use was
multiplied by the unit costs to estimate the cost per partic-
ipant. Table 1 details the key unit costs, together with their
sources [15–19].
Outcome measures
The primaryhealth outcome for the cost-effectiveness anal-
ysis was assessed in terms of quality-adjusted life-years
(QALYs). QALY is a generic health outcome measure that
is recommended by the National Institute for Health and
Care Excellence (NICE) for economic evaluation [14]. Com-
pared toclinicaloutcomemeasures, suchasquit rate,which
vary between studies in terms of length of time quit, length
of follow-up andmeans of measurement, the QALYpermits
comparisons between different health-care programmes
[20]. NICEhas speciﬁed an explicit decision-making thresh-
old range for what should be considered cost-effective;
namely, if an intervention has an incremental cost of less
than £20000–30000 per additional QALY gained, while
there is no similar threshold given in quit rates. In addition,
the use of QALYs also allows us to compare the short- and
long-term beneﬁts from the trial interventions.
Wemeasured participants’ health states using a generic
measure of health status; namely, the EQ-5D questionnaire
at baseline and 6-month follow-up [21]. The EQ-5D scores
were converted to utilities using the UK population tariff,
and QALYs were calculated using the area under the curve
approach [22–24]. The secondary outcomes were the pro-
portion of participants entering the SSS during a period of 6
months and the proportion of participants quitting
smoking at the 6-month follow-up.
Cost-effectiveness analysis
A full cost-effectiveness analysis (CEA) was conducted on
an ‘intention-to-treat’ (ITT) basis, where all participants
are analysed as randomized. Incremental cost-effectiveness
ratios (ICERs) were used to combine differential mean costs
and the effects associated with the two trial groups in a sin-
gle measure to which a decision rule for cost-effectiveness
can be applied [20]:
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ICER ¼ ΔC
ΔE
¼ CI  CC
EI  EC
where E represents the effects and C represents the costs of
the intervention, measured in monetary units, and the
subscripts ‘I’ and ‘C’ refer to the intervention and control
arm, respectively.
Missing data were imputed using Rubin’s multiple im-
putation (MI) method [25–27]. Chained imputation using
predictive meanmatching over 50 imputations was under-
taken to estimate cost and EQ-5D data items when they
were missing. The following independent covariates were
speciﬁed for the imputation model: intervention group, re-
source use data and baseline EQ-5 D score, smoking absti-
nence and participant characteristics such as age and
gender.
To account for the uncertainty due to sampling
variation in cost-effectiveness, a non-parametric bootstrap
re-sampling technique was employed to obtain conﬁdence
intervals for the ICERs by generating 5000 iterations of
the mean cost and QALYs for each trial group. [28–31]. A
total of 50 imputations were generated to ensure efﬁcient
and reproducible estimates. Cost-effectiveness acceptability
curves (CEACs) were plotted based on the outcomes of the
bootstrap iterations to show the probability of the interven-
tion beingmore cost-effective than the control over a range
of a decision-maker’s willingness-to-pay (WTP) thresholds
[32]. All the analyses were conducted with Stata version
13.0 (StataCorp, College Station, TX, USA). Statistical sig-
niﬁcance was accepted at P< 0.05 in each of the analyses.
Long-term costs and outcome predictions
Numerous studies have demonstrated that the majority of
beneﬁts of smoking cessation are gained from the reduced
risk of developing smoking-related diseases, and the re-
duced health-care costs and improved health-related qual-
ity of life it brings over a longer period [3,33]. These
beneﬁts may not be evident until later in life, therefore
long-term cost-effectiveness of the two-component person-
alized intervention compared with control was estimated
in addition to the short-term within-trail analysis. We esti-
mated the life-time health-care cost savings and QALYs as-
sociatedwith the two trial interventions using the results of
two high-quality published studies [34,35].
The life-time health-care cost for smokers and quitters
are derived fromaMarkovmodel built byAli and colleagues
[34]. The model used a comprehensive modelling frame-
work to represent the clinical pathways and their conse-
quences associated with smoking and smoking cessation.
Costs of smoking are deﬁned by theWorld Health Organiza-
tionas thedifferencebetweenhealth careor other costs that
actuallyoccurdue tosmokingand thecosts thatwouldhave
Table 1 Unit costs (and sources) employed to estimate total costs (in 2012–13 prices).
Resource item Unit Cost Source
Smoking cessation aids
NHS Stop Smoking Services
Group session Per person per session £4.6 [16]
Individual session Per person per session £17 [16]
Telephone £5.9 per call at 2008–09 price £6.4 [17]
Drop-in Per person per session £17 [16]
Couple/family Per person per session £8.5 [16]
Other non-pharmacological smoking cessation aids
GP visit 10-minute brief advice session £40 [15]
Practice nurse 10-minute brief advice session £7 [15]
Pharmacist 10-minute brief advice session £11 [15]
NHS smoking helpline £5.9 per call at 2008–09 price £6.4 [17]
Other smoking helpline £5.9 per call at 2008–09 price £6.4 [17]
Pharmacological smoking cessation aids
Nicotine replacement therapy (NRT) Per prescription item £21 [18]
Zyban: bupropion Per prescription item £38 [18]
Champix® (Pﬁzer): varenicline Per prescription item £34 [18]
Wider health-care resource use
GP visit Visit (average 11.7 minutes) £37 [15]
Practice nurse visit Visit (average 15.5 minutes) £11 [19]
Day case Finished consultant episode £693 [19]
In-patient (cost per night) Per bed night £542 [19]
Out-patient attendance Visit £108 [19]
Accident and emergency attendance Visit £114 [19]
NHS = National Health Service; GP = general practice.
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occurred had there been no smoking [36]. This model esti-
mated health-care cost savings due to the changing risk of
clinical conditions that are known have signiﬁcant health
and economic consequences for smokers and quitters, such
as lung cancer, chronic obstructive pulmonary disease
(COPD), myocardial infarction and stroke. In the absence
of estimated life-time QALY gains in this model, we com-
bined and utilized another English study by Vogl and col-
leagues which reported age- and gender-speciﬁc EQ-5D
values according to smoking status [35]. Relevant life-time
cost savings and QALY gains were attached to the partici-
pantsbyage,genderandsmokingstatustoestimate life-time
outcomes associated with the two interventions. Future
costs and health outcomes were discounted at 3.5% per
annum [14]. The same non-parametric bootstrap method
was used to derive long-termCEACs to express the probabil-
ity that the intervention is cost-effective as a function of the
willingness-to-pay thresholds during a life-time horizon.
Sensitivity analysis
In order to explore the potential impact of missing data on
the estimated intervention effects and costs, a sensitivity
analysis was undertaken to repeat the cost-effectiveness
analysis using complete cases, whereby the results were
analysed only for those participants who had both com-
plete cost and outcome data.
Patient involvement
The interests of all parties and the views of the public have
been represented fully in the conduct of this study from the
design stage onwards. A past successful user of the Camden
SSS was invited onto the Trial Management Group as a pa-
tient representative and has been fully involved at all Trial
Management Group (TMG) meetings. She contributed to
the design of both parts of the intervention, to the conduct
of the trial and collection of data andwas particularly help-
ful with suggestions of how to maximize response rate to
the follow-up. This patient representative also added
greatly to the discussion of the results and of the practical
implications of this method of recruitment to the SSS.
In addition, another past user of the Camden SSS also
contributed to the development of both parts of the
intervention. Both service users were consulted on the
content of the brief personal letter at all stages of develop-
ment and on the protocol for the taster sessions. Both users
also narrated their own experiences of quitting, and these
were used to create the video which formed a part of the
taster session. A lay report of the results has been prepared
for dissemination to all participating SSSs and general
practices, who will also distribute the report to all
interested study participants.
RESULTS
In the cost-effectiveness analysis, 4383 participants were
analysed. The sample was 51% male, and the mean age
was 49 years. Full details of the trial participants and clin-
ical outcomes are given in the accompanying paper [12].
Resource use and costs
Table 2 summarizes the mean [and standard deviation
(SD)] cost for the interventions and the subsequent use of
health services during the 6-month follow-up period. The
costs of delivering the trial intervention and the costs asso-
ciated with the smoking cessation aids were signiﬁcantly
higher in the intervention group. Participants’ total cost re-
lies heavily upon their wider health resource use, but there
were no signiﬁcant differences in the use of resources dur-
ing the 6-month follow-up. After adjusting for baseline re-
source use, the tailored letter and taster sessions cost an
overall mean of £92 more per participant than the generic
letter, with 95% conﬁdence intervals (CI) crossing zero
(£32 to £216).
Outcome measures
The primary health economic outcome was QALYs for 6
months. QALYs for the intervention and control were
Table 2 Average cost by category and treatment allocation [prices in GBP (£) in 2012–13].
Intervention group n = 2635
Mean (SD)
Control group n = 1748
Mean (SD)
Differencea (£)
(95% CI)
Intervention cost £54 (£12) £0.9 (£1) £53 (£52 to £53)
NHS SSS attendance cost £11 (£34) £5 (£23) £6 (£4 to £8)
Other non-pharmacological cessation aids £44 (£32) £40 (£26) £4 (£2 to £6)
Pharmacological cessation aids £61 (£49) £50 (£32) £10 (£8 to £13)
Wider health-care resource use cost £608 (£2175) £583 (£1860) £25 (£99 to £149)
Total cost £777 (£2176) £679 (£1860) £98 (£26 to £222)
Adjusted total costb £760 (£2039) £669 (£2059) £92 (£32 to £216)
The numbers may not add up due to rounding. CI = conﬁdence interval; SD = standard deviation; NHS SSS = National Health Service Stop Smoking Services.
aDifference = costs for intervention group – costs for control group; badjusted for baseline cost.
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estimated to be 0.382 (SD = 0.046) and 0.380
(SD = 0.046), respectively, after adjusting for the baseline
utility scores (Table 3). However, the difference in QALYs
between the two trial groups was not signiﬁcant. Results
of the secondary outcome measures are also given in
Table 3. In this study, we applied a range of criteria to assess
the throughput and success rates of the interventions, and
the main outcome for quitting was the 7-day point preva-
lent abstinence as validated by salivary cotinine at the 6-
month follow-up. Both the proportion of people attending
the SSS and the quit rates were signiﬁcantly higher in the
intervention group than in the control group.
Cost-effectiveness analysis
ICERs were used to combine the costs and health beneﬁts
in a single measure to assess the incremental cost-
effectiveness of the trial intervention (Table 3). The ad-
justed mean costs were £92 higher and the adjusted mean
QALYs were 0.002 higher in the intervention group com-
pared with the control group. This generates an ICER of
£59401 (95% CI = –£604833 to 644486) per QALY
gained. Figure 1 shows the cost-effectiveness plane (CEP)
representing 5000 bootstrapped resamples of the
difference in costs and difference in QALYs when compar-
ing the intervention group with the control group. The
cost-effectiveness acceptability curve (CEAC) (Fig. 2) illus-
trates that the probability that the tailored letter and taster
session is more cost-effective than the generic letter at 6
months is well below 50%, over a NICE decision-making
threshold range of £20000–30000 per QALY gained.
Only at higher WTP thresholds (> £59401 per QALY)
does the intervention become more likely to be cost-
effective compared with the control.
Table 3 also shows the total costs in relation to the
other outcome measures. Four hundred and ﬁfty-eight
(17.4%) smokers in the treatment group and 158 (9.0%)
smokers in the control group attended the SSS. The aver-
age costs incurred in the intervention group and control
group were £54 and 0.9, respectively, resulting in an ICER
of £627 per additional attendee to the SSS. The cost per ad-
ditional quitter ranged from £1699 to 4053 according to
the criteria for abstinence. For themain quit rate (biochem-
ical validation of 7-day abstinence), the corresponding
ICERwas £2689 (95% CI = –£952 to 6329) per additional
quitter. This indicates that if decision-makers are willing to
pay more than £627 to help one more smoker to attend
the SSS, or £2689 to generate an additional quitter, the
Table 3 Outcome measures and incremental cost-effectiveness ratios (ICERs).
Intervention group
n = 2635
Control group
n = 1748
Differencea
(95% CI) ICERs
QALY
Mean (SD)
QALY Mean
(SD)
Difference
(95% CI)
ICER (cost per QALY gained)
(95% CI)
Unadjusted QALYs 0.381 (0.141) 0.380 (0.136) 0.0001 (0.009 to
0.008)
£ 862629 (£742154 to
£1 159 241)
Adjusted QALYs (adjusted for
baseline cost and EQ-5D scores)
0.382 (0.046) 0.380 (0.046) 0.002 (0.001 to
0.004)
£59401 (£604833 to
£644 486)
Attendance at
SSS (n, %)
Attendance at
SSS (n, %)
Odds ratio (95% CI) ICER (cost per additional
person attending NHS SSS)
(95% CI)
Attendance at SSS 458 (17.4%) 158 (9.0%) 2.12 (1.75 to 2.57) £627 (£620 to £634)
Smoking outcome Quitter (n, %) Quitter (n, %) Odds ratio (95% CI) ICER (cost per additional
quitter) (95% CI)
24-hour pp abstinence
(self-report)
445 (16.9%) 201 (11.5%) 1.57 (1.31 to 1.88) £1700 (£602 to £4001)
7-day pp abstinence
(validated)
236 (9.0%) 97 (5.6%) 1.68 (1.32 to 2.15) £2689 (£952 to £6329)
7-day pp abstinence
(self-report)
424 (16.1%) 187 (10.7%) 1.61 (1.34 to 1.94) £1699 (£601 to £3998)
1-month prolonged
abstinence (self-report)
357 (13.6%) 151 (8.6%) 1.67 (1.36 to 2.04) £1866 (£660 to £4392)
3-month prolonged
abstinence (validated)
150 (5.7%) 60 (3.4%) 1.70 (1.25 to 2.31) £4053 (£1435 to £9541)
3-month prolonged
abstinence (self-report)
240 (9.1%) 103 (5.9%) 1.61 (1.26 to 2.04) £2849 (£1008 to £6706)
aDifference = costs/effects for the intervention group – costs/effects for the control group; pp = per person. CI = conﬁdence interval; QALY = quality-adjusted
life-years; NHS SSS = National Health Service Stop Smoking Services.
Increasing attendance at the NHS SSS 5
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
tailored letter and taster session would be the preferred
option, otherwise usual care should be adopted.
Long-term costs and outcome predictions
The cost-effectiveness analysis was extrapolated to the life-
time time horizon using QALYs as the outcome measure.
The life-time accumulative QALY gains by smoking status,
gender and age group, both before and after discounting,
are summarized in Table 4. The life-time horizon was
deﬁned as the participant’s remaining life-time between
the age they entered the trial and the time they reach the
national average life expectancy at birth (81 years in
2013 in the United Kingdom) [37]. Overall life-time health
costs due to smoking-related diseases for both smokers and
ex-smokers were derived from the published economic
model and are listed in Table 5 [34]. Participants in the
intervention group were expected to have health-care cost
savings of £210 (before discounting) and £74 (after
discounting) during their life-time compared to those in
the control group. At the same time, they have higher
life-time QALY gains of 0.470 (before discounting) and
0.196 (after discounting) than people in the control group.
The negative ICERs suggest that, during the participants’
life-time, tailored letters and taster sessions generate more
QALY gains at a lower cost, indicating that the interven-
tion is more cost-effective than the control condition.
Figure 3 presents CEACs for long-term cost-effectiveness.
Using the NICE decision-making threshold range of
£20000–30000 per QALY gained, the probability that
Intervention more costly
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the intervention was more cost-effective was 83% before
discounting and 86% after discounting in the long term,
which suggests that the intervention is a good use of NHS
resources.
Sensitivity analysis
Sensitivity analysis was carried out to investigate the ro-
bustness of the results. Complete cost and cost-effectiveness
data were available for 1667 (63%) of participants in the
intervention group and 1108 (63%) of participants in the
control group. The results of the complete case analysis
were very similar to those from the primary analysis, and
results from both analyses are summarized in Table 6. For
both trial groups, the average costs and the gains in cost-
effectiveness were slightly higher in the complete cases,
and the ICERs decreased slightly. Figure 4 shows the CEAC
with QALY as the outcome measure from the complete
Table 4 Cumulative life-time QALY gains by gender and age group.
Cumulative life-time QALY gains by gender and age group (before discounting)
Life-time QALY gain (male) 16–24 25–34 35–44 45–54 55–64 65–74 75–79
Ex-occasional smokera 65.603 46.986 37.555 28.379 19.675 11.574 3.706
Ex-regular smoker 64.914 46.461 37.155 28.097 19.501 11.481 3.679
Light smoker 64.196 46.010 36.744 27.742 19.216 11.299 3.615
Moderate smoker 63.341 45.433 36.267 27.368 18.946 11.131 3.556
Heavy smoker 61.915 44.463 35.492 26.764 18.505 10.858 3.463
Life-time QALY gain (female) 16–24 25–34 35–44 45–54 55–64 65–74 75–83
Ex-occasional smoker 49.664 45.974 36.868 27.877 19.284 11.354 3.540
Ex-regular smoker 49.002 45.369 36.381 27.509 19.030 11.203 3.494
Light smoker 48.622 44.997 36.059 27.245 18.827 11.079 3.448
Moderate smoker 48.006 44.425 35.590 26.874 18.557 10.909 3.389
Heavy smoker 46.874 43.377 34.747 26.225 18.095 10.629 3.293
Cumulative life-time QALY gains by gender and age group (after discounting)
Discounted life-time QALY gain (male) 16–24 25–34 35–44 45–54 55–64 65–74 75–79
Ex-occasional smoker 22.421 20.530 18.032 14.924 11.165 6.370 3.347
Ex-regular smoker 22.137 20.287 17.832 14.776 11.067 6.320 3.322
Light smoker 21.992 20.117 17.648 14.589 10.903 6.218 3.264
Moderate smoker 21.732 19.874 17.424 14.394 10.749 6.124 3.211
Heavy smoker 21.274 19.463 17.060 14.078 10.497 5.971 3.127
Discounted life-time QALY gain (female) 16–24 25–34 35–44 45–54 55–64 65–74 75–83
Ex-occasional smoker 22.201 20.558 18.379 15.590 12.267 8.062 5.385
Ex-regular smoker 21.901 20.288 18.136 15.385 12.105 7.956 5.315
Light smoker 21.762 20.132 17.980 15.234 11.973 7.863 5.246
Moderate smoker 21.497 19.885 17.749 15.026 11.797 7.737 5.156
Heavy smoker 20.997 19.423 17.332 14.661 11.499 7.531 5.010
Ex-regular smokers: people who used to smoke sometimes but have now quit; light smokers: smokers who smoke fewer than 10 cigarettes a day; moderate
smokers: smokers who smoke between 10 and 19 cigarettes a day; heavy smokers: smokers who smoke 20 or more cigarettes a day. aEx-occasional smokers:
people who have smoked only once or twice. QALY = quality-adjusted life-years.
Table 5 Long-term cost-effectiveness results.
Before discounting Discounted
Intervention group
(n = 2635)
Control group
(n = 1748)
Intervention group
(n = 2635)
Control group
(n = 1748)
Life-time cost (mean, SD) £19 390 (£2776) £19 601 (£2787) £5775 (£1109) £5848 (£1114)
Cost differencea –£210 (£432 to £11) –£74 (£–162 to £15)
Life-time QALY gains (mean, SD) 27.009 (11.894) 26.539 (11.943) 13.974 (4.424) 13.778 (4.442)
QALY differencea 0.470 (0.478 to 1.419) 0.196 (0.157 to 0.549)
ICER (cost per QALY gained)
(95% CI)
–£447 (95% CI = –£4368 to £3646) –£376 (95% CI = –£3881 to £3207)
aDifference = costs/effects for the intervention group – costs/effects for the control group. QALY = quality-adjusted life-years; SD = standard deviation;
ICER = incremental cost-effectiveness ratios; CI = conﬁdence interval.
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Figure 3 Life-time cost-effectiveness acceptability curve (before and after being discounted) [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
Table 6 Summary of the cost-effectiveness results from the multiple imputation analysis versus completed case analysis.
Multiple imputation analysis Complete case analysis
Intervention group
(n = 2635)
Control group
(n = 1748)
Intervention group
(n = 1667)
Control group
(n = 1108)
Adjusted total cost (mean, SD) £760 (£2039) £669 (£2059) £851 (£2455) £724 (£2465)
Cost difference (£) (95% CI) £92 (£32 to £216) £127 (£60 to £314)
Adjusted QALY at 6 months 0.382 (0.046) 0.380 (0.046) 0.384 (0.052) 0.382 (0.053)
QALY difference (95% CI) (mean, SD) 0.002 (0.001 to 0.004) 0.003 (0.044 to 0.055)
ICER (cost per QALY gained) (95% CI) £59 401 (£604833 to £644486) £49842 (£425064 to £536 813)
Intervention cost (mean, SD) £54 (£12) £0.9 (£1) £55 (£13) £0.9 (£2)
Attendance at SSS (n, %) 458 (17.4%) 158 (9.0%) 334 (20.0%) 102 (9.2%)
ICER (cost per additional attendee NHS
SSS) (95% CI)
£627 (£620 to £634) £498 (£491 to £504)
Validated 7-day abstinence at 6 months 236 (8.96%) 97 (5.55%) 214 (12.84%) 87 (7.85%)
ICER (cost per additional quitter) (95%CI) £2689 (£952 to £6329) £2552 (£1199 to £6303)
QALY = quality-adjusted life-years; SD = standard deviation; ICER = incremental cost-effectiveness ratios; CI = conﬁdence interval.
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case analysis. The probability of the intervention being
more cost-effective compared to the control group in-
creased slightly, but the overall conclusion remains the
same. The complete case results appeared to be robust
compared with the analyses including imputed data.
DISCUSSION
Although smoking prevalence in the United Kingdom has
remained unchanged in recent years, the use of NHS Stop
Smoking Services has continued to decline sharply [8]. The
Start2quit trial is a timely study to explore new interven-
tions to increase the take-up of the SSS, and ultimately to
increase the number of successful quit attempts. There
are similar studies in the literature investigating the effec-
tiveness of interventions to increase the attendance at the
SSS [38,39] but this is the ﬁrst study that has estimated
the cost-effectiveness of the intervention to inform smokers
about the services.
Our main ﬁnding was that, compared with the generic
letter, the tailored letter plus the taster session is likely to be
more effective but more costly. The within-trial cost-
effectiveness analysis shows that in the short term, i.e. 6
months, the intervention is less likely to be cost-effective
compared with the control. However, in common with
many preventive interventions, the majority of beneﬁts
from stopping smoking are gained from the reduced risks
of developing smoking-related diseases, such as lung can-
cer and COPD, later in life [3,33]. The 6-month follow-up
of the trial is therefore insufﬁcient to capture the longer-
term health beneﬁts of the intervention [20,27,40]. The
long-term cost-effectiveness analysis, which considered
the life-time cost savings and QALY gains from the two
interventions, suggests that the tailored letter and taster
sessions had a greater than 83% chance of being more
cost-effective compared with the standard generic letter
at WTP thresholds, ranging between £20000 and
30000 per QALY gained.
The direct intervention costs were, as expected,
higher in the tailored letter and taster session group
than in the generic letter group (£54 versus 0.9), due
to the complex design of the intervention. In the inter-
vention group, 60% of the total £54 cost was spent on
sending baseline questionnaires to gather information
for generating the tailored letter, while for the control
group the baseline questionnaires were used only for
research purposes, and this cost was considered as a
research cost and hence excluded from the analysis. A
potential way to reduce the intervention cost is to use
cheaper alternatives, such as e-mails, to reach smokers
to obtain any information needed for the tailored letter.
However, the response rates may be lower from e-mails
compared with traditional postal questionnaires and
further studies are recommended [41]
During the trial period, smokers in the intervention
group were more likely to use smoking cessation aids, both
from the SSS and from other sources. The mean cost of SSS
attendance was more than twice in the intervention group
than in the control group (£11 versus 5), which indicates
that the intervention greatly increased the usage of the
SSS. The use of other pharmacological and non-
pharmacological cessation aids, such as GP, nurse, phar-
macist visits and smoking helplines, were also signiﬁcantly
higher in the intervention group, but other, wider, health-
care resource uses not linked directly to smoking cessation
were not signiﬁcantly different between the two groups.
In the long-term cost-effectiveness analysis, we took
into account only the direct health-care costs for treating
smoking-related disease, and other indirect costs of
smoking, such as productivity losses due to smoking-related
diseases and premature death, costs of accidental ﬁres and
second-hand smoking, were not included [42] Therefore,
the intervention could generate more cost savings and be-
comemore cost-effective ifwe take into account the indirect
costs of smoking, given that the quit rate was signiﬁcantly
higher in the intervention group than in the control group.
Strengths and limitations of the study
To the best of our knowledge, the present study is the ﬁrst
full economic evaluation alongside a large RCT to have
assessed the cost-effectiveness of a two-component inter-
vention designed to increase attendance at the SSS in the
United Kingdom. A particular strength of the study is that
we assessed the cost-effectiveness of the intervention both
in the short term and during a life-time horizon. The pri-
mary analysis used a full imputed data set, but we also car-
ried out complete case analysis in a sensitivity analysis to
test the robustness of the results. The conclusion remained
robust after analysis of the statistical uncertainty.
However, our study had several limitations. The pri-
mary outcomemeasure used in the study was QALYs mea-
sured by EQ-5D, which is a widely applied generic
instrument for measuring the quality of life. However, it
may not be able to capture all aspects of quality of life
changes for smokers, especially in the short term. The ad-
justed QALY difference between the two groups was very
small within the trial period [0.002 QALYs (95%
CI = –0.001 to 0.004)], which resulted in very high ICERs
at the 6-month point [£59401 per additional QALY gained
(95% CI = –£604833 to 644486)]. The high ICERs led
subsequently to the conclusion that the intervention is
not cost-effective in the short term, because it far exceeded
the NICE WTP threshold (£30000 per QALY gained).
In the long-term cost-effectiveness analysis, all quitters
were assumed to remain abstinent from smoking after the
intervention. Due to the complexity of smoking behaviour
the risk of relapse for quitters is very high but, conversely,
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many smokers may achieve quitting smoking spontane-
ously, i.e. self-initiated smoking cessation without interven-
tions [43] Therefore, further studies, such as RCTs with
longer follow-up periods or the use of models that consider
the changes in smoking behaviour, are needed.
In conclusion, using thewithin-trial data, the use of tai-
lored letters and taster sessions is a more costly and more
effective intervention compared with the standard generic
letter, but is unlikely to be cost-effective during the short
term. However, quitting smoking yields far greater
health-care cost savings and health beneﬁts during the
long-term through the reduced risk of developing
smoking-related diseases. The long-term results indicate
that during a life-time horizon the tailored letter and taster
sessions become more effective and less costly, and this in-
tervention has a great probability of being more cost-
effective at more than 86% using the £20000–30000
per QALY gained decision-making threshold.
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